|Day's range||0.7600 - 1.0700|
These Dow Jones laggards logged double-digit declines in May. Are their fortunes turning, or is more misery on the way?
The competition in retail pharmacy is intense. Neither of these stocks has been a winner for investors over the last 12 months. Here's how two Motley Fool contributors think CVS and Walgreens stack up against each other.
Walgreens (WBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DEERFIELD, Ill., June 05, 2023--WBA will release its fiscal 2023 third quarter results at 7 a.m. ET on Tuesday, June 27, 2023.
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
Walgreens Boots Alliance (WBA) closed the most recent trading day at $30.32, moving -0.16% from the previous trading session.
Investors may want to resist the temptation to load up on a dividend that could end up being too good to be true.
Vitamin Angels and Walgreens have announced the expansion of their prenatal pilot program to nearly 400 Walgreens stores nationwide, including a direct ship option in certain markets. The program provides free prenatal vitamins and nutrition education materials to pregnant people in underserved communities through participating Walgreens pharmacies.
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
The problem this time around is another instance of one of the company's bugbears over the last few years: legal settlements pertaining to its filling of opioid drug prescriptions. The latest piece of bad news is that Walgreens agreed on May 17 to a $230 million settlement with the city of San Francisco, which was suing it for lack of sufficient due diligence when it filled prescriptions for opioid medications.
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $30, marking a +0.1% move from the previous day.
Shares of the pharmaceutical services leader have fallen close to 17% so far this year while the S&P 500 has risen nearly 8%. Walgreens could be poised to rebound, though. Wall Street expects the stock to skyrocket by 30%.
The Dow Jones Industrial Average is composed of 30 time-tested, multinational businesses. Three of them are capable of delivering triple-digit total returns over the next five years.
DEERFIELD, Ill., May 25, 2023--Walgreens is pleased to announce the winners and finalists for our 13th annual Expressions by Walgreens art challenge. The national contest provides monetary awards to winning high school student submissions from around the country.
Household name and dividend growth stock Walgreens Boots Alliance (NASDAQ: WBA) hasn't been good to shareholders for some time now. Walgreens is transitioning its business beyond prescriptions and retail stores and is working through a bloated balance sheet from an acquisition spree over the past few years. Here is where Walgreens stands and whether you should consider buying shares or wait it out.
The Dow Jones Industrial Average was the best-performing of the three major indexes in 2022, but 2023 hasn't been as kind to the blue chip index. The regional banking crisis has hit the Dow hard, and the rebound in tech stocks has also left it lagging behind the S&P 500 and Nasdaq Composite, which have more exposure to the tech sector. As you can see from the chart below, the Dow is actually down slightly for the year even as the other two indexes have delivered solid gains.
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
The stock doesn't have a great track record, but could that change as it pivots toward healthcare?
DEERFIELD, Ill., May 17, 2023--To honor the service and sacrifices of Americans who served in the armed forces, Walgreens is offering a weekend Memorial Day discount to all veterans, active-duty military personnel and their immediate family members, including the families of those who lost their lives in service to their country.
Whether or not you buy the highest-yielding Dow stocks depends on how you invest. Here is a look at each of them.
Walgreens remains bullish on its clinical trials segment as rival CVS announces closure.
DEERFIELD, Ill., May 12, 2023--Walgreens Boots Alliance sells shares of AmerisourceBergen Corporation for $694 million of initial proceeds.
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $31.17, marking a -1.33% move from the previous day.
Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.